{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:27:08Z","timestamp":1791113228623,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.euroneuro.2010.04.010","type":"journal-article","created":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T12:38:45Z","timestamp":1275395925000},"page":"683-687","source":"Crossref","is-referenced-by-count":28,"title":["Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa"],"prefix":"10.1016","volume":"20","author":[{"given":"A.","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bondiolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Natuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Bareggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2010.04.010_bib1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/mds.21500","article-title":"Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome","volume":"22","author":"Antonini","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1468-1331.2007.02043.x","article-title":"Bimodal administration of entacapone in Parkinson's disease patients improves motor control","volume":"15","author":"Bet","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1742-1241.1995.tb09988.x","article-title":"Quality of life and care in Parkinson's disease","volume":"49","author":"Clarke","year":"1995","journal-title":"Br. J. Clin. Pract."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.410240303","article-title":"Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part 1","volume":"24","author":"Fabbrini","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib5","series-title":"Recent Developments in Parkinson's Disease","first-page":"153","article-title":"Unified Parkison's disease rating scale","author":"Fahn","year":"1987"},{"key":"10.1016\/j.euroneuro.2010.04.010_bib6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.69.5.584","article-title":"Health related quality of life in Parkinson's disease: a prospective longitudinal study","volume":"69","author":"Karlsen","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.04.010_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","article-title":"Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease","volume":"41","author":"Kostic","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2010.04.010_bib9","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.43.9.1698","article-title":"Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa\/carbidopa in Parkinson's disease patients with \u2018on-off\u2019 fluctuations","volume":"43","author":"Kurth","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2010.04.010_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","article-title":"Tolcapone decrease plasma levels of S-adenosyl-l-homocysteine and homocystiene in treated Parkinson's disease patients","volume":"62","author":"M\u00fcller","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0304-3940(01)01972-3","article-title":"Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease","volume":"308","author":"M\u00fcller","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","article-title":"Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease","volume":"64","author":"Nyholm","year":"2005","journal-title":"Neurology"},{"issue":"10 suppl","key":"10.1016\/j.euroneuro.2010.04.010_bib14","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinson's disease","volume":"23","author":"Olanow","year":"2000","journal-title":"Trends Neurosci."},{"issue":"5","key":"10.1016\/j.euroneuro.2010.04.010_bib15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","author":"Parkinson Study Group","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.68.5.589","article-title":"The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease","volume":"68","author":"Piccini","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.04.010_bib17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/archneur.64.8.1083","article-title":"Treatment options in the modern management of Parkinson disease","volume":"64","author":"Shapira","year":"2007","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.euroneuro.2010.04.010_bib19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.25.12.1144","article-title":"On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients","volume":"25","author":"Shoulson","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2010.04.010_bib20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent versus continuous levodopa administration in patients with advanced Parkinson's disease","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2010.04.010_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0731-7085(91)80140-5","article-title":"Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography","volume":"9","author":"Wikberg","year":"1991","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T10:34:55Z","timestamp":1685615695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X10000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0924977X10000921"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2010.04.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}